Emphysema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Emphysema is a lung disease that affects the alveoli (tiny air sacs). The alveoli become abnormally inflated in emphysema, damaging their walls and making breathing difficult. Emphysema is a type of COPD (chronic obstructive pulmonary disease). The cause of emphysema is usually long-term exposure to irritants that damage your lungs and the airways.
·
The prevalence of emphysema in the United
States is approximately 14 million, which includes 14% white male smokers and
3% white male nonsmokers. The prevalence is slightly less for white female
smokers and African Americans.
Thelansis’s “Emphysema Market Outlook,
Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Emphysema
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Emphysema across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Emphysema Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech business
environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment